10,037 Shares in Livongo Health (NASDAQ:LVGO) Acquired by Concorde Asset Management LLC

Concorde Asset Management LLC acquired a new position in Livongo Health (NASDAQ:LVGO) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 10,037 shares of the company’s stock, valued at approximately $1,406,000. Livongo Health accounts for about 0.8% of Concorde Asset Management LLC’s investment portfolio, making the stock its 26th biggest holding.

Several other hedge funds also recently bought and sold shares of LVGO. Patriot Financial Group Insurance Agency LLC increased its position in shares of Livongo Health by 106.4% in the third quarter. Patriot Financial Group Insurance Agency LLC now owns 194 shares of the company’s stock worth $27,000 after purchasing an additional 100 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Livongo Health in the third quarter worth approximately $33,000. D Orazio & Associates Inc. bought a new position in Livongo Health during the third quarter valued at approximately $42,000. Skandinaviska Enskilda Banken AB publ bought a new position in Livongo Health during the second quarter valued at approximately $47,000. Finally, Glenmede Trust Co. NA bought a new position in Livongo Health during the second quarter valued at approximately $48,000. Institutional investors own 41.67% of the company’s stock.

LVGO stock traded down $0.91 on Monday, reaching $138.00. The company’s stock had a trading volume of 35,667 shares, compared to its average volume of 3,015,559. The business has a fifty day simple moving average of $135.34 and a two-hundred day simple moving average of $94.01. Livongo Health has a 12-month low of $18.76 and a 12-month high of $151.05. The firm has a market cap of $14.11 billion, a PE ratio of -346.14 and a beta of 1.77. The company has a debt-to-equity ratio of 0.69, a quick ratio of 19.51 and a current ratio of 19.88.

Livongo Health (NASDAQ:LVGO) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.17. Livongo Health had a negative return on equity of 4.86% and a negative net margin of 12.76%. The company had revenue of $91.90 million during the quarter, compared to analyst estimates of $86.68 million. During the same quarter last year, the firm posted ($0.46) earnings per share. The firm’s revenue was up 124.1% on a year-over-year basis. As a group, research analysts anticipate that Livongo Health will post -0.05 earnings per share for the current fiscal year.

A number of research analysts have commented on the stock. Credit Suisse Group assumed coverage on shares of Livongo Health in a research report on Tuesday, July 14th. They set an “outperform” rating and a $132.00 price target on the stock. Stephens assumed coverage on shares of Livongo Health in a research report on Monday, July 6th. They set an “overweight” rating and a $95.00 price target on the stock. KeyCorp increased their price target on shares of Livongo Health from $85.00 to $105.00 in a research report on Tuesday, July 7th. Goldman Sachs Group cut shares of Livongo Health from a “buy” rating to a “neutral” rating and increased their price target for the company from $48.00 to $70.00 in a research report on Thursday, July 2nd. Finally, Citigroup increased their price objective on Livongo Health from $125.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Seven research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $94.94.

In other Livongo Health news, CFO Lee Shapiro sold 5,734 shares of the firm’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $132.53, for a total transaction of $759,927.02. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Glen Tullman sold 422,000 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $124.50, for a total value of $52,539,000.00. Following the transaction, the chairman now directly owns 1,348,199 shares of the company’s stock, valued at approximately $167,850,775.50. The disclosure for this sale can be found here. Insiders sold 691,865 shares of company stock valued at $86,180,389 in the last ninety days. 13.00% of the stock is currently owned by insiders.

Livongo Health Company Profile

Livongo Health, Inc provides an integrated suite of solutions for the healthcare industry in North America. It solutions promote health behavior change based on real-time data capture supported by intuitive devices and insights driven by data science. The company offers a platform that provides cellular-connected devices, supplies, informed coaching, data science-enabled insights, and facilitates access to medications.

See Also: What is the Consumer Price Index (CPI)?

Want to see what other hedge funds are holding LVGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Livongo Health (NASDAQ:LVGO).

Institutional Ownership by Quarter for Livongo Health (NASDAQ:LVGO)

Receive News & Ratings for Livongo Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Livongo Health and related companies with MarketBeat.com's FREE daily email newsletter.